Portal de Periódicos da CAPES

“Inactive” excipients such as Cremophor can affect in vivo drug disposition

2003; Wiley; Volume: 73; Issue: 5 Linguagem: Inglês

10.1016/s0009-9236(03)00010-9

1532-6535

Cristoph Wandel, Richard B. Kim, C. Michael Stein,

Pharmaceutical studies and practices

Clinical Pharmacology & TherapeuticsVolume 73, Issue 5 p. 394-396 Commentaries "Inactive" excipients such as Cremophor can affect in vivo drug disposition Cristoph Wandel MD, Cristoph Wandel MD Hoffmann-La Roche, Basel, and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USASearch for more papers by this authorRichard B. Kim MD, Richard B. Kim MD Hoffmann-La Roche, Basel, and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USASearch for more papers by this authorC. Michael Stein MD, Corresponding Author C. Michael Stein MD Hoffmann-La Roche, Basel, and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USARobinson Research Building, Room 560, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6602, USA. E-mail: [email protected]Search for more papers by this author Cristoph Wandel MD, Cristoph Wandel MD Hoffmann-La Roche, Basel, and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USASearch for more papers by this authorRichard B. Kim MD, Richard B. Kim MD Hoffmann-La Roche, Basel, and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USASearch for more papers by this authorC. Michael Stein MD, Corresponding Author C. Michael Stein MD Hoffmann-La Roche, Basel, and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USARobinson Research Building, Room 560, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6602, USA. E-mail: [email protected]Search for more papers by this author First published: 17 May 2003 https://doi.org/10.1016/S0009-9236(03)00010-9Citations: 14Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Tayrouz, Y., Ding, R., Burhenne J.,Riedel K-D., Weiss J., Hoppe-Tichy T., et al. (2003). Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther 73: 397–405. 2Bailey, D. G., Arnold, J. M., Munoz, C. and Spence, J. D. (1993). Grapefruit juice–felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 53: 637–642. 3Dresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., Dawson, P. A. and Freeman, D. J., et al. (2002). Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71: 11–20. 4Tsunoda, S. M., Harris, R. Z., Christians, U., Velez, R. L., Freeman, R. B. and Benet, L. Z., et al. (2001). Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 70: 462–467. 5Darbar, D., Dell'Orto, S., Morike, K., Wilkinson, G. R. and Roden, D. M. (1997). Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 61: 292–300. 6Dresser, G. K., Wacher, V., Wong, S., Wong, H. T. and Bailey, D. G. (2002). Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 72: 247–255. 7Pifferi, G., Santoro, P. and Pedrani, M. (1999). Quality and functionality of excipients. Farmaco 54: 1–14. 8Baldrick, P. (2000). Pharmaceutical excipient development: the need for preclinical guidance. Regul Toxicol Pharmacol 32: 210–218. 9Scott, A. W. (1990). Non-medicinal ingredients. Drug Safety 5 (Suppl 1): 95–100. 10Boman, G., Lundgren, P. and Stjernstrom, G. (1975). Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: adsorption of rifampicin by an excipient, bentonite. Eur J Clin Pharmacol 8: 293–299. 11Sparreboom, A., Verweij, J., van der Burg, M. E., Loos, W. J., Brouwer, E. and Vigano, L., et al. (1998). Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4: 1937–1942. 12Schuurhuis, G. J., Broxterman, H. J., Pinedo, H. M., van Heijningen, T. H., van Kalken, C. K. and Vermorken, J. B., et al. (1990). The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br J Cancer 62: 591–594. 13Chang, T., Benet, L. Z. and Hebert, M. F. (1996). The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 59: 297–303. 14Wandel, C., Kim, R. B., Wood, A. J. J. and Stein, C. M. (2001). "Inactive" ingredients may alter bioavailability of drugs through effects on P-glycoprotein (PGP) and CYP3A [abstract]. Clin Pharmacol Ther 69: P66. 15Wandel, C., Kim, R. B., Kajiji, S., Guengerich, P., Wilkinson, G. R. and Wood, A. J. (1999). P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59: 3944–3948. 16Rege, B., Kao, J. and Polli, J. (2002). Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16: 237–246. 17Cornaire, G., Woodley, J. F., Saivin, S., Legendre, J. Y., Decourt, S. and Cloarec, A., et al. (2000). Effect of polyoxyl 35 castor oil and polysorbate 80 on the intestinal absorption of digoxin in vitro. Arzneimittelforschung 50: 576–579. 18Bardelmeijer, H. A., Ouwehand, M., Malingre, M. M., Schellens, J. H., Beijnen, J. H. and van Tellingen, O. (2002). Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother Pharmacol 49: 119–125. 19Malingre, M. M., Schellens, J. H., van Tellingen, O., Ouwehand, M., Bardelmeijer, H. A. and Rosing, H., et al. (2001). The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 85: 1472–1477. Citing Literature Volume73, Issue5May 2003Pages 394-396 ReferencesRelatedInformation